TrialAnnals of the rheumatic diseases2020

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.

James R Seibold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.